Biomedical Occupation or Discipline – Page 9

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

5 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

Mass Layoffs at HHS: Trump Administration Cuts Thousands of Probationary Workers

5 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), HHS layoffs, NIH Mouse, public health medicine (field), Transplant Registry Unified Management Program, United States Food and Drug Administration, Workers

HHS layoffs, probationary employees, Trump administration, CDC, NIH, FDA, federal workforce reduction, public health impact

Trump Establishes Make America Healthy Again Commission to Combat Childhood Chronic Diseases

5 months ago talkbio0Tagged CHARGE Syndrome, Chronic disease, Commission, disease prevention, MAHA, public health medicine (field), Robert F. Kennedy Jr., Secretary

MAHA Commission, Robert F. Kennedy Jr., childhood chronic diseases, HHS Secretary, Executive Order, public health, chronic illness, disease prevention

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

5 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

5 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

5 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

5 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

5 months ago talkbio0Tagged AnaptysBio, Immunology, Increase, Prices, RENOIR, Rheumatoid Arthritis, Rosnilimab, Treatment Effectiveness

AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

5 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay